Publications by authors named "A Mogenet"
Background: In the clinic, the primary conventional treatments of advanced non-small cell lung cancer (NSCLC) are surgery, radiation therapy, and chemotherapy. In recent years, immune checkpoint inhibitors (ICIs) have shown promise in optimizing therapeutic benefits when combined with other immunotherapies or standard therapies. However, effective biomarkers for distant metastasis or recurrence have yet to be identified, making it difficult to determine the best therapeutic approaches.
View Article and Find Full Text PDFBackground: Prophylactic cranial irradiation (PCI) is recommended to decrease the incidence of brain metastases (BM) in extensive-stage small-cell lung cancer (ESSCLC) without BM after response to chemotherapy. However, PCI is associated with significant neurocognitive effects, and new studies are debating its benefits. Moreover, the introduction of immunotherapy in the management of the disease has raised new questions, and there is a lack of data on PCI and immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Interstitial lung disease (ILD) is associated with an increased risk of lung cancer (LC), but the surgical risks for patients with both conditions remained uncertain, prompting a study analyzing outcomes for LC patients with and without ILD.
- The study included data from 4,073 patients who underwent LC surgery between January 2006 and June 2023, with 30 identified as having ILD. Key findings showed no significant difference in overall survival between LC-ILD and LC-non-ILD groups, although the LC-ILD group faced specific complications like prolonged air leaks and pneumonia.
- Overall, the research illustrates that while patients with LC-ILD experience certain challenges, surgical outcomes, including post-operative complications, are not significantly worse
Intracranial progression after curative treatment of early-stage non-small cell lung cancer (NSCLC) occurs from 10 to 50% and is difficult to manage, given the heterogeneity of clinical presentations and the variability of treatments available. The objective of this study was to develop a mechanistic model of intracranial progression to predict survival following a first brain metastasis (BM) event occurring at a time [Formula: see text]. Data included early-stage NSCLC patients treated with a curative intent who had a BM as the first and single relapse site (N = 31).
View Article and Find Full Text PDF